Skip to content
Screener

D&A at other companies

Amgen logo
AmgenAMGN
$1.11B-17.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$123.7M-8.4%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$107K-6.1%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$851K-8.4%
Savara logo
SavaraSVRA
$28K-17.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$130K-11.0%

Other financials

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$394.54M-54.7%
Enterprise value$316.1M-61.6%
P/S124.9×-195×

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%
Debt / equity0.0×
Current ratio28×-10.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-343417

FAQ

What is Upstream Bio, Inc.'s D&A?
Upstream Bio, Inc. (UPB) reported D&A of $50K in Q2 2026.
How has Upstream Bio, Inc.'s D&A changed year-over-year?
Upstream Bio, Inc.'s D&A increased by 19.0% year-over-year, from $42K to $50K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Ask your AI about Upstream Bio, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude